Pregled bibliografske jedinice broj: 551716
Diclofenac Encephalopathy, Liver and Gastrointestinal Lesions in Rat and Stable Gastric Pentadecapeptide BPC 157
Diclofenac Encephalopathy, Liver and Gastrointestinal Lesions in Rat and Stable Gastric Pentadecapeptide BPC 157 // Abstracts of the ….. ; u: Gastroenterology 138 (2010) (5/S1) ; M1274, 2010. str. S-369 (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 551716 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Diclofenac Encephalopathy, Liver and Gastrointestinal Lesions in Rat and Stable Gastric Pentadecapeptide BPC 157
Autori
Ilić, Spomenko ; Drmić, Domagoj ; Kolenc, Danijela ; Čorić, Marijana ; Brčić, Luka ; Klicek, Robert ; Radić, Božo ; Sever, Marko ; Đuzel, Viktor ; Filipović, Marinko ; Ivica, Mihovil ; Boban Blagaić, Alenka ; Anić, Tomislav ; Zoričić, Ivan ; Gjurašin, Miroslav ; Romić, Željko ; Džidić, Senka ; Seiwerth, Sven ; Sikirić, Predrag
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the ….. ; u: Gastroenterology 138 (2010) (5/S1) ; M1274
/ - , 2010, S-369
Mjesto i datum
,
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
Diclofenac encephalopathy; liver; gastrointestinal lesions; BPC 157; rats
Sažetak
Combined diclofenac encephalopathy, liver and gastrointestinal lesions have not yet been established in rats. The stable gastric pentadecapeptide, BPC 157 (GEPPPGKPADDAGLV, MW 1419, efficient in inflammatory bowel disease trials (PL 14736) and various wound treatment, no toxicity reported) is an anti-ulcer peptide with hepatoprotective effects that may also affectmany central disturbances. Diclofenac (12.5mg/kg)was given intraperitoneally once daily for 3 subsequent days. BPC 157 (10μg/kg, 10ng/kg) was given either (i) intraperi-toneally immediately after diclofenac or (ii) per-orally in drinking water (0.16 μg/ml, 0.16 ng/ml) up until the end of the experiment. At 3 h following the last diclofenac challenge, we evidenced severe gastric, intestinal and liver lesions, increased bilirubin, AST, ALT serum values, liver weight, prolonged sedation/unconsciousness (after any diclofenac challenge) and finally (hepatic) encephalopathy (Fig.1, C (control) B (BPC 157)). Brain edema was particularly present in the cerebral cortex and cerebellum, more in white than in gray matter, damaged (balloonized) red neurons were particularly expressed in the cerebral cortex and cerebellar nuclei, Purkinje cells and less expressed in hippocampal neurons. This was consistently counteracted in diclofenac-rats that received BPC 157 (μg- or ng-regimen, intraperitoneally or per-orally). In conclusion, the successful counteraction of combined diclofenac encephalopathy, liver and gastrointestinal lesions by BPC 157 regimens means that besides inflammatory bowel disease, diclofenac toxicity may be a new domain for possible BPC 157 therapy.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Sikirić, Predrag, MZOS ) ( CroRIS)
108-1083570-3636 - Učinak BPC 157 na induciranu bilijarnu opstrukciju (Anić, Tomislav, MZOS ) ( CroRIS)
108-1083570-3643 - Kvantitativna analiza i prijenos slike u patologiji (Seiwerth, Sven, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Miroslav Gjurašin
(autor)
Luka Brčić
(autor)
Robert Kliček
(autor)
Predrag Sikirić
(autor)
Danijela Kolenc
(autor)
Alenka Boban Blagaić
(autor)
Marko Sever
(autor)
Senka Džidić
(autor)
Spomenko Ilić
(autor)
Željko Romić
(autor)
Sven Seiwerth
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE